倍他乐克对高血压性心脏病QTd及VA的影响  

Effect of Betaloc on QTd and ventricular arrhythmia in patients with hypertension heart disease

作　　者：程峰[1] 刘俊[1] 陶春明[1] 周利民[1] 刘玉[1] 

机构地区：[1]安徽医科大学滁州临床学院心内科,239000

出　　处：《中华全科医学》2014年第6期930-931,共2页Chinese Journal of General Practice

摘　　要：目的探讨倍他乐克对高血压性心脏病（HHD）患者心电图QT间期离散度（QTd）及室性心律失常（VA）的影响。方法将80例高血压性心脏病患者随机分为2组，对照组40例给予基础治疗，治疗组40例在基础治疗上加用倍他乐克25—100mg／d，疗程1年。治疗前后测QTd及24小时动态心电图。结果治疗前治疗组QTd为（71．75±14．03）ms，VA发生率为35％，对照组分别为（68．60±14．99）ms和35％；治疗后治疗组QTd为（60．83±15．00）ms，vA发生率为15％，对照组分别为（67．73±11．96）ms和25％，治疗组治疗前后差异有统计学意义（P〈0．05），而对照组治疗前后差异无统计学意义。2组比较，治疗组明显优于对照组。结论HHD患者长期应用倍他乐克可明显降低QTd及室性心律失常的发生率，有利于改善患者预后。Objective To explore the influence of Betaloc on QT interval dispersion （QTd）and ventricular arrhythmia （VA） in patients with hypertension heart disease（HHD）. Methods Total 80 patients with HHD were recruited in this study and randomly divided into treatment group and control group with 40 cases in each group. The control group received the initial therapy ,while the treatment group received Betaloc 25 - 100 mg/d based on the initial therapy. The course was one year. QTd and 24-hour Hoher were recorded before and after the treatment. Results Before the treatment, the QTd was（71.75 ± 14.03） ms and the incidence of VA was 35% in the treatment group, （68.60 ± 14.99 ）ms and 35%, re- spectively, in the control group;After the treatment, the results were 60.83 ± 15.00 ）ms and 15 % in the treatment group （ P 〈 0.05 ）, and （ 67.73 ± 11.96 ） ms and 25 % in the control group, respectively （ P 〉 0.05 ）. The differences were stati- cally significant between the two groups. Conclusion Long-term using of Betaloc to treat HHD can significantly reduce patients＇ Q-Td and the incidence of VA and improve the prognosis of patients.

关 键 词：倍他乐克 高血压性心脏病 QT间期离散度 室性心律失常 

分 类 号：R541.3[医药卫生—心血管疾病] R541.7[医药卫生—内科学]